Immuneering (IMRX) - 2024 Q4 - Annual Results

Exhibit 99.1 Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate IMM-1-104 in combination with Libtayo® (cemiplimab) in non-small cell lung cancer - - Additional IMM-1-104 Phase 2a d ...